<DOC>
	<DOCNO>NCT01364415</DOCNO>
	<brief_summary>This study design determine Maximum Tolerated Dose ( MTD ) patient advanced Neuroendocrine Tumors ( NETs ) characterize safety , tolerability , Pharmacokinetics preliminary efficacy pasireotide LAR administer i.m . every 28 day .</brief_summary>
	<brief_title>Dose Escalation Study Pasireotide ( SOM230 ) Patients With Advanced Neuroendocrine Tumors ( NETs )</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<criteria>≥18 yr old , histologically confirm advanced well moderately differentiate neuroendocrine tumor/carcinoma unresectable metastatic NET tumor measurable disease life expectancy ≥ 12 week Patients CNS metastases neurologically unstable require increase dos steroid control CNS disease patient know hypersensitivity somatostatin analogs patient symptomatic cholelithiasis past 2 month patient history another know primary malignancy exception nonmelanoma skin cancer carcinoma situ uterine cervix patient know history hepatitis C chronic active hepatitis B patient diagnosis HIV . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>MTD</keyword>
	<keyword>pasireotide</keyword>
	<keyword>LAR</keyword>
	<keyword>NETs</keyword>
	<keyword>advanced neuroendocrine tumor</keyword>
</DOC>